01/24/23 6:00 AMOTC : HMTXF InvestmentPitch Media Video Discusses Hemostemix and its Hiring of 4 Biotechnologists to Re-Establish Production of ACP-01 in Montreal and Applying for Grants to Fund Up to 75% of 5-Year ExpensesHemostemix Inc. (TSXV:HEM) (OTCQB:HMTXF) (FSE:2VF0), an autologous stem cell therapy company, is hiring four biotechnologists to re-establish the company’s production of ACP-01 in Montreal. This staffing requirement arose because ofRHEA-AIneutral
01/23/23 6:00 AMOTC : HMTXF clinical trialInvestmentPitch Media Video Discusses Hemostemix and its $250,000 in Funding from McGill University Health Centre Foundation for Clinical Trial of ACP-01Hemostemix Inc. (TSXV:HEM) (OTCQB:HMTXF), an autologous stem cell therapy company, has received a $250,000 Letter of Commitment for funding from the McGill University Health Centre (MUHC) Foundation. Under the Letter of Commitment,RHEA-AIneutral
